arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

SOLIGENIX, INC.

SNGX
$0.39 0.00 (+1.01%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

SOLIGENIX, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.2M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -25.0%
FCF / Share $-0.11
Trailing P/E
Price / Book 1.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-1.99M
↑ +26.4%
Operating Margin Operating profit as % of sales
-297.8%
↑ +38.3%
FCF / Share Free cash flow per share
$-0.11
↑ +87.2%
Long-Term Debt Long-term obligations
$1.01M
↓ -28.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Financial Health
8
Cash Quality
62

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 17 years · 67 quarters